Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × Immunotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 36 Melanoma 14 Neoplasm Metastasis 13 Lung Neoplasms 12 Esophageal Neoplasms 10 Carcinoma, Hepatocellular 10 Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 7 Colorectal Neoplasms 7 Breast Neoplasms 7 Esophageal Squamous Cell Carcinoma 6 Stomach Neoplasms 5 Rectal Neoplasms 5 Head and Neck Neoplasms 5 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Uterine Cervical Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Liver Neoplasms 3 Cholangiocarcinoma 3 Brain Neoplasms 3 Sarcoma 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Neuroblastoma 2 Neoplasm, Residual 2 Locally Advanced Non-small Cell Lung Cancer 2

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡